PFE, has entered a global licensing agreement with Novavax to use Matrix-M adjuvant technology in the development of up to ...

Maryland-based Novavax signed a licensing agreement allowing Pfizer access to its technology that boosts immune responses to vaccines.

The pharma company had to scale vaccine production from 200 million annually to 3 billion at the pandemic's peak.

Under the terms of the agreement, Pfizer is expected to pay an upfront total of $30 million in early 2026 to Novavax, while holding the potential to provide up to $500 million more in development and ...

Novavax’s Pfizer Matrix-M licensing deal brings $30M upfront, milestones & royalties. Read the full analysis here.

Pfizer (NYSE:PFE) has entered a non exclusive licensing agreement with Novavax for access to its Matrix-M adjuvant technology. The company is also participating in the White House TrumpRx initiative, ...

Pfizer is paying $30 million to use Novavax’s adjuvant technology to improve the efficacy of two of the Big Pharma’s vaccine programs. The tech, called Matrix-M, is designed to trigger an immune ...

In today’s ACT Brief, we look at how global clinical development is evolving through decentralized models and emerging markets, why site-centric practices are becoming critical to faster study ...

By Michael Erman and Christy Santhosh Jan 20 (Reuters) - Novavax said on Tuesday it signed a licensing agreement allowing Pfizer access to its technology that boosts immune responses to vaccines for ...